Browse drugs

…: p=0,0482; Anti-IL12/23 vs Anti-TNF: p=0,0480; Risankizumab vs Ustekinumab: p=0,0116. No significant differences were found between Risank…

…50%). However, 79% required a 3rd line agent, most of which was Anti-IL12/23 (50%). 29% required a 4th line agent and 10% were on a 5th line…